Shaping the Trajectory of Trials by Understanding the Benefits of Multicentre, Placebo-Controlled Studies for IgAN
Time: 3:30 pm
day: Conference Day One
Details:
- Understanding the pathogenesis of IgAN and why proliferation-inducing ligands could be an ideal target
- Outlining the advantages of a phase 3 randomized controlled trial to assess the efficacy and safety for IgAN drug development
- Using eGFR and uPCR as surrogate endpoints and their capabilities to shorten clinical trials
